This SPA agreement marks an important milestone in the development of Descartes-08 for MG, providing critical regulatory clarity and a clear path toward potential approval,” said Carsten Brunn, Ph.D., ...
Japan’s Nippon Shinyaku is continuing to scoop up the international rights to some intriguing drugs, this time penning a $686 million biobucks deal for AB2 Bio’s late-stage autoimmune disease therapy.
After being diagnosed with a rare disease—indolent systemic mastocytosis (ISM)—and starting on a treatment that has reduced her ISM symptoms, she continues to adapt and is inspired to help ...
THEY KNEW IT WAS AUTOIMMUNE, BUT EVERY TIME THEY TRIED ... THEN IN 2019, AN ANSWER FINALLY ARRIVED THROUGH THE UNDIAGNOSED DISEASES NETWORK, ROSA SYNDROME, A NAME AS COMPLEX AS THE CONDITION ...